95 related articles for article (PubMed ID: 25090760)
1. [Prevention and screening of cervical cancer].
Rakotomahenina H; Garrigue I; Marty M; Brun JL
Rev Prat; 2014 Jun; 64(6):780-5. PubMed ID: 25090760
[TBL] [Abstract][Full Text] [Related]
2. [Cervical cancer prevention: the impact of HPV vaccination].
Monsonégo J
Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969
[TBL] [Abstract][Full Text] [Related]
3. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
Tota J; Mahmud SM; Ferenczy A; Coutlée F; Franco EL
Sex Health; 2010 Sep; 7(3):376-82. PubMed ID: 20719230
[TBL] [Abstract][Full Text] [Related]
4. Challenges in cervical cancer prevention: a survey of U.S. obstetrician-gynecologists.
Perkins RB; Anderson BL; Gorin SS; Schulkin JA
Am J Prev Med; 2013 Aug; 45(2):175-81. PubMed ID: 23867024
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus infection and cervical cancer prevention in Japan and Korea.
Konno R; Shin HR; Kim YT; Song YS; Sasagawa T; Inoue M; Park JS
Vaccine; 2008 Aug; 26 Suppl 12():M30-42. PubMed ID: 18945412
[TBL] [Abstract][Full Text] [Related]
7. [Cervical cancer screening and associated treatment costs in France].
Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
9. Impact of pap test compliance and cervical cancer screening intervals on human papillomavirus vaccine acceptance.
Ferris DG; Waller J; Dickinson A; McCracken C; Goebel A
J Low Genit Tract Dis; 2012 Jan; 16(1):39-44. PubMed ID: 22126831
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.
Tay SK; Ngan HY; Chu TY; Cheung AN; Tay EH
Vaccine; 2008 Aug; 26 Suppl 12():M60-70. PubMed ID: 18945415
[TBL] [Abstract][Full Text] [Related]
11. Will vaccinated women attend cervical screening? A population based survey of human papillomavirus vaccination and cervical screening among young women in Victoria, Australia.
Brotherton JM; Mullins RM
Cancer Epidemiol; 2012 Jun; 36(3):298-302. PubMed ID: 22204834
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
14. HPV testing and vaccination in Europe.
Leeson SC; Alibegashvili T; Arbyn M; Bergeron C; Carriero C; Mergui JL; Nieminen P; Prendiville W; Redman CW; Rieck GC; Quaas J; Petry KU
J Low Genit Tract Dis; 2014 Jan; 18(1):61-9. PubMed ID: 23774078
[TBL] [Abstract][Full Text] [Related]
15. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
16. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination.
Franco EL; Ferenczy A
Future Oncol; 2007 Jun; 3(3):319-27. PubMed ID: 17547527
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus: science and technologies for the elimination of cervical cancer.
Bosch FX
Expert Opin Pharmacother; 2011 Oct; 12(14):2189-204. PubMed ID: 21756205
[TBL] [Abstract][Full Text] [Related]
18. The current and future role of screening in the era of HPV vaccination.
Myers E; Huh WK; Wright JD; Smith JS
Gynecol Oncol; 2008 May; 109(2 Suppl):S31-9. PubMed ID: 18482556
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus infection and the primary and secondary prevention of cervical cancer.
Lowy DR; Solomon D; Hildesheim A; Schiller JT; Schiffman M
Cancer; 2008 Oct; 113(7 Suppl):1980-93. PubMed ID: 18798536
[TBL] [Abstract][Full Text] [Related]
20. Recommendations for cervical cancer prevention in Asia Pacific.
Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
